Related Experiment Video

Updated: May 23, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

[PARP inhibitors and breast cancer: update and perspectives]

Anthony Gonçalves1

  • 1Institut Paoli-Calmettes, oncologie médicale, Marseille, France. goncalvesa@marseille.fnclcc.fr

Bulletin Du Cancer
|March 28, 2012
PubMed

Insights

Poly(ADP-ribose) polymerase (PARP) inhibitors show promise for breast cancer, especially in BRCA1/2-mutated tumors via synthetic lethality. Further research is needed to optimize PARP inhibitor treatments and identify predictive biomarkers for improved efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Poly(ADP-ribose) polymerase (PARP) is a key target in cancer therapy.
  • PARP inhibitors exploit synthetic lethality in homologous recombination deficient tumors like those with BRCA1/2 mutations.
  • PARP inhibitors are used as monotherapy or in combination with chemotherapy for breast cancer.

Purpose:

  • To review the therapeutic potential of PARP inhibitors in breast cancer.
  • To highlight the challenges and future directions for PARP inhibitor development.

Summary:

  • PARP inhibitors induce selective tumor cell death in BRCA1/2-mutated breast cancers.
  • A recent trial combining iniparib with chemotherapy in triple-negative metastatic breast cancer showed no survival benefit.
  • This outcome underscores the need for optimized treatment schedules, novel combinations, and predictive biomarkers.

Impact:

  • Advances in understanding synthetic lethality offer new therapeutic strategies for breast cancer.
  • The findings emphasize the need for further research to overcome limitations in current PARP inhibitor therapies.
  • Development of predictive biomarkers is crucial for patient selection and treatment efficacy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...